Estimate of infectiousness during COVID-19

Understanding the transmission of SARS-CoV-2 is complicated by the large numbers of presymptomatic, asymptomatic, and mildly symptomatic (PAMS) patients. The reproductive number, R0, is a measure of population-level dynamics, but it cannot provide information on infectiousness of different groups such as PAMS subjects; when peak infectiousness occurs; and the effect of intrinsic properties of the …

Estimate of infectiousness during COVID-19 Read More »

Holiday travel explains spread of a SARS-CoV-2 variant

The emergence and spread throughout Europe of a SARS-CoV-2 variant, 20E (EU1) in the summer of 2020 illustrates how a virus may become dominant not by increased transmissibility but through travel and lack of effective containment and screening. The SARS-CoV-2 variant 20E (EU1) emerged in Spain in the summer of 2020 and spread to multiple …

Holiday travel explains spread of a SARS-CoV-2 variant Read More »

TWiV 659: Sloppy coronavirus immunity with Christian Drosten

Christian Drosten returns to TWiV to provide an update on the COVID-19 situation in Germany, and general thoughts on testing, immunity, vaccines, therapeutics, epidemiology, reopening schools, and what will happen this fall. Click arrow to playDownload TWiV 659 (72 MB .mp3, 120 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at

The Route Matters

by Gertrud U. Rey There are currently 315 therapeutic drugs and 210 vaccine candidates in development to treat or prevent SARS-CoV-2 infection. Many of these vaccines are designed to be administered by injection into the muscle.  Intramuscular injection of a vaccine antigen typically induces a systemic (serum) immune response that involves the action of IgM and IgG …

The Route Matters Read More »

Scroll to Top